Hubertus von Baumbach, EFPIA president (Credit: EFPIA via YouTube)
September 30, 2022 02:53 PM EDTUpdated 03:21 PM
R&D

Eu­ro­pean phar­ma group wants to cre­ate PRV-like sys­tem to spur an­tibi­otics R&D

Zachary Brennan

Senior Editor

New re­search fund­ed by a Eu­ro­pean phar­ma in­dus­try group is look­ing to rein­vig­o­rate an­timi­cro­bial R&D with a sys­tem that’s sim­i­lar to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times